- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02448537
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
PM01183 is a new drug that is believed to bind DNA cause double strands of DNA to break. This drug has been studied in previous research studies, and these suggest that it may slow or stop the growth of cancers. The FDA (the U.S. Food and Drug Administration) has not approved PM01183 as a treatment for any disease.
In this research study, the investigators are trying to assess the effects, good or bad, that PM01183, administered either alone or in combination with gemcitabine or doxorubicin has on metastatic or unresectable sarcoma.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must have pathologically confirmed soft-tissue sarcoma, which is metastatic or unresectable, sarcoma with no curative multimodality options
- Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- No more than two prior lines of chemotherapy for metastatic sarcoma are allowed; Neo-adjuvant/adjuvant chemotherapy with definitive therapy (radiation, surgery or radiation and surgery) will not be counted as one of these prior lines of therapy.
- Age ≥ 18 and ≤ 75 years.
- Eastern Cooperative Oncology Group performance status ≤1 (see Appendix A)
- Life expectancy of greater than 3 months
Participants must have normal organ and marrow function as defined below:
- Hemoglobin ≥ 9 g/dl
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcL
- total bilirubin ≤ 1.5 X ULN
- AST(SGOT)/ALT(SGPT) ≤3 X ULN (including patients with liver metastases)
- creatinine ≤1.5 X ULN
- CPK < 2.5 X ULN
- Albumin ≥ 3 g/dl
- Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to receiving study agents.
- For patients in stratum A, an echocardiogram or multiple gated acquisition scan (MUGA) demonstrating left ventricular ejection fraction > 50% is required within 30 days prior to study drug administration.
- Participants must be willing and able to comply with the study scheduled visits, laboratory tests, and other procedures outlined in the protocol.
- Pre-menopausal women must have a negative pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuation. Acceptable methods of contraception include intrauterine device (IUD), oral contraceptive, subdermal implant, double barrier and/or complete abstinence (non-periodic).
Washout period prior to Day 1 Cycle 1:
- ≥ 3 weeks since last chemotherapy or therapeutic radiation therapy (RT)
- ≥ 4 weeks or 3 half-lives since prior antibody-based therapy, whichever is shorter
- ≥ 2 weeks since any oral anti-neoplastic or oral investigational agent
- Resolution of treatment-related toxicity to ≤ grade 1; alopecia and cutaneous toxicity are allowed ≤ grade 2.
- ≥1 week since palliative RT
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Prior exposure to PM01183
- Patients who have received trabectedin (Yondelis, ET-743) or participated in the phase III clinical study of trabectedin NCT01343277 previously will not be eligible.
- For stratum A, patients must not have received prior anthracycline-based therapy (prior treatment with non-anthracyclines is permitted).
- For stratum B patients must have received prior anthracycline-based therapy (or have a contraindication to receiving this treatment) and must not have received prior gemcitabine
- For stratum C, patients must have received prior anthracycline or gemcitabine-based therapy, or had a contraindication to either or both
- Prior radiation treatment of >45 Gy to the pelvis
- Previously untreated Ewing Sarcoma and rhabdomyosarcoma
- Non-soft tissue sarcomas, such as osteosarcoma and chondrosarcoma are excluded
- Participants who are receiving any other investigational agents.
- Active hepatopathy of any origin including active hepatitis B and hepatitis C
- Participants with known uncontrolled brain metastases will be excluded from this clinical.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PM01183 or trabectedin (Yondelis, ET-743).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, chronic indwelling drains, history of interstitial pneumonitis or pulmonary fibrosis or psychiatric illness/social situations that would limit compliance with study requirements.
- Actively breastfeeding women unless it is interrupted during treatment and at least 6 weeks after treatment discontinuation.
- Known myopathy or persistent CPK elevations >2.5 ULN in two different determinations performed one week apart.
- Immunocompromised patients, including those with HIV.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PM01183 and Doxorubicin
Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.
|
Other Names:
Other Names:
|
EXPERIMENTAL: PM01183 and Gemcitabine
Prior anthracycline exposure and without prior gemcitabine exposure
|
Other Names:
Other Names:
|
EXPERIMENTAL: Single Agent PM01183
Patients who have received at least both prior anthracycline and prior gemcitabine -PM01183 predetermined dose once via IV per cycle |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate
Time Frame: 24 Weeks
|
The number of participants that achieved either Stable Disease (SD) or a Partial Response (PR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) at 24 weeks.
|
24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: Every 6 weeks for the first 8 cycles (cycle is 21 days) and then every 9 weeks thereafter until disease progression
|
The overall response rate is the number of participants that achieved either Stable Disease (SD), a Partial Response (PR), or a Complete Response (CR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The overall response rate is the best response recorded from the start of treatment until disease progression/recurrence.
|
Every 6 weeks for the first 8 cycles (cycle is 21 days) and then every 9 weeks thereafter until disease progression
|
Treatment Related Serious Adverse Events
Time Frame: From the start of treatment until 30 days after the end of treatment
|
Summary of the serious adverse events (SAE) experienced by participants that were deemed to be at least possibly related to PM01183 when administered alone or with Doxorubicin or Gemcitabine.
Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE v4).
|
From the start of treatment until 30 days after the end of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gregory Cote, MD PhD, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Sarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Gemcitabine
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- 15-083
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Sarcoma
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
Fred Hutchinson Cancer CenterIncyte CorporationActive, not recruitingRefractory Soft Tissue Sarcoma | Metastatic Leiomyosarcoma | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Synovial Sarcoma | Metastatic Chondrosarcoma | Advanced Leiomyosarcoma | Metastatic Myxoid... and other conditionsUnited States
-
Roswell Park Cancer InstituteRecruitingColorectal Cancer | Metastatic Unresectable Sarcoma | Metastatic Malignant Neoplasm in the Lung | Resectable Sarcoma | Metastatic Soft Tissue Sarcoma | Metastatic Bone SarcomaUnited States
-
OHSU Knight Cancer InstituteNovartis Pharmaceuticals; Oregon Health and Science UniversityCompletedStage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Locally Advanced Leiomyosarcoma | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable... and other conditionsUnited States
-
Massachusetts General HospitalJazz PharmaceuticalsRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Advanced Leiomyosarcoma | Leiomyosarcoma MetastaticUnited States
-
David DickensWithdrawnSoft Tissue Sarcoma | Bone Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft-tissue Sarcoma | Metastatic Bone Sarcoma | Unresectable Bone SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
Providence Health & ServicesCompletedMetastatic Sarcoma | Metastatic Carcinoma | Metastatic LymphomaUnited States
-
Wuhan Union Hospital, ChinaRecruitingSoft Tissue Sarcoma | Neoplasms, Connective and Soft Tissue | Sarcoma Metastatic | Sarcoma,Soft TissueChina
-
National Cancer Institute (NCI)CompletedStage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditionsUnited States
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting